Kadmon shares jump on limited IPF data; Cellectis granted two US patents for editing T cells with CRISPR
→ Kadmon shares $KDMN spiked on some Phase II data they’re touting on on a ROCK2 inhibitor for idiopathic pulmonary fibrosis. It’s a
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
